SAB Biotherapeutics (SABS) Change in Interest Receivables (2024 - 2026)
SAB Biotherapeutics (SABS) posted Change in Interest Receivables of $608280.0 for Q1 2026, up 57.25% on a QoQ basis from $386827.0 in Q4 2025, and up 1912.03% year-over-year from $30232.2 in Q1 2025.
SAB Biotherapeutics (SABS) Change in Interest Receivables (2024 - 2026) Analysis & Trends
SAB Biotherapeutics' Change in Interest Receivables history runs 3 years deep, the most recent figure standing at $608280.0 for Q1 2026.
- Quarterly Change in Interest Receivables rose 1912.03% year-over-year to $608280.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 992.47% YoY) and the FY2025 annual result came in at $891826.0, up 1522.83% from the prior year.
- Change in Interest Receivables was $608280.0 for Q1 2026 at SAB Biotherapeutics, up from $386827.0 in the prior quarter.
- Across five years, Change in Interest Receivables topped out at $608280.0 in Q1 2026 and bottomed at -$127877.0 in Q3 2024.
- A 3-year average of $172784.6 and a median of $31692.0 in 2024 frame the typical range for Change in Interest Receivables.
- Annual changes were most pronounced in 2025 — Change in Interest Receivables tumbled 167.48% — and 2026, when it soared 1912.03%.
- SAB Biotherapeutics' Change in Interest Receivables stood at -$42092.0 in 2024, then soared by 1019.0% to $386827.0 in 2025, then jumped by 57.25% to $608280.0 in 2026.
- Business Quant data shows SABS's Change in Interest Receivables at $608280.0 in Q1 2026, $386827.0 in Q4 2025, and $559954.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Interest Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - | 608,280.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 608,280.00 |
| Dec 31, 2025 | 386,827.00 |
| Sep 30, 2025 | 559,954.00 |
| Jun 30, 2025 | -21,386.00 |
| Mar 31, 2025 | -33,569.00 |
| Dec 31, 2024 | -42,092.00 |
| Sep 30, 2024 | -127,877.00 |
| Jun 30, 2024 | 31,692.00 |
| Mar 31, 2024 | 193,232.00 |